SEARCH

SEARCH BY CITATION

References

  • 1
    Mannucci PM, Tuddenham EDG. The hemophilias – from royal genes to gene therapy. N Engl J Med 2001; 344: 17739.
  • 2
    Tabor E. The epidemiology of virus transmission by plasma derivatives. clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 11608.
  • 3
    Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transf Med Rev 1999; 13: 194204.
  • 4
    Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 9215.
  • 5
    Ludlam CA. New variant Creutzfeldt-Jakob disease and treatment of hemophilia. Lancet 1999; 350: 1704.
  • 6
    Esmonde TF, Will RG, Slattery JM, Knight R, Harries-Jones R, De Silva R, Matthews WB. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 2057.
  • 7
    Heye N, Hensen S, Muller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994; 343: 2989.
  • 8
    Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38: 81720.
  • 9
    Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE. Retrospective neuropathological review of prion disease in UK hemophilic patients. Thromb Haemost 1998; 80: 90911.
  • 10
    Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. J General Virol 2002; 83: 2897905.
  • 11
    Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002; 42: 1497500.
  • 12
    National Hemophilia Foundation. Medical Advisory. West Nile Virus #392 and 393, 2002. eNews@hemophilia.org.
  • 13
    Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ. Human recombinant DNA-derived anti-hemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 18005.
  • 14
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy and development of inhibitors. Kogenate Previously Untreated Patients Study Group. N Engl J Med 1993; 328: 4539.
  • 15
    Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Safety Study. Blood 1994; 83: 242835.
  • 16
    Abshire T, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 2000; 38: 8116.
  • 17
    Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 4451.
  • 18
    Tarantino MD, Novale LM, Bray GL, Ewenstein BM. Clinical evaluation of a new generation recombinant FVIII, plasma/albumin-free method (rAHF-PFM). Blood 2002; 100: 493a.
  • 19
    White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35 (Suppl. 2): 338.
  • 20
    Mannucci PM. Treatment of hemophilia: recombinant factors only? No. J Thromb Haemost 2003; 1: 2168.
  • 21
    Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 110.
  • 22
    Mannucci PM, Ghirardini A. Desmopressin: twenty years after. Thromb Haemost 1997; 78: 958.
  • 23
    Saenko EL, Ananyeva NM, Shima M, Hauser CAE, Pipe S. The future of recombinant coagulation factors. J Thromb Haemost 2003; 1: 92230.
  • 24
    Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 5648.
  • 25
    Schwarz HP, Lenting PJ, Binder B, Mihaly J, Denis C, Dorner F, Turecek PL. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 17038.
  • 26
    Turecek PL, Schwarz HP, Binder BR. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood 2000; 95: 36378.
  • 27
    Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 119709.
  • 28
    Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 4215.
  • 29
    Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, Van Geijlswijk JL, Van Houwelingen H, Van Asten P, Sixma JJ. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: A double-blind clinical trial. N Engl J Med 1981; 305: 71721.
  • 30
    Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex vs proplex: a controlled, double blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 11358.
  • 31
    Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 5427.
  • 32
    Van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 13305.
  • 33
    Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 17756.
  • 34
    Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 6989.
  • 35
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitor. Thromb Haemost 1998; 80: 9128.
  • 36
    Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 226.
  • 37
    Ingerslev J, Friedman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M. Major surgery in haemophiliac patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26: 11823.
  • 38
    Smith MP, Ludlam CA, Collins PW, Hay CRM, Wilde JT, Gringeri A, Melsen Tr, Savidge GF. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 94953.
  • 39
    Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 9548.
  • 40
    Himmelspach M, Richter G, Muhr E, Varadi K, Turecek PL, Dorner F, Peter Schwarz H, Schlokat U. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo. Thromb Haemost 2002; 88: 100311.
  • 41
    Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 18195.
  • 42
    Mauser-Bunschoten EP, Nieuwenhuis KH, Rosendaal G, Van Den Berg HM. Low dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 9838.
  • 43
    DiMichele DM, Kroner BL and the North American Immune Tolerance Study Group. The North American immune tolerance registry. Practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 527.
  • 44
    Lacroix-Desmazes S, Misra N, Bayry J, Artand C, Drayton B, Kaveri SV, Kazatchkine MD. Pathophysiology of inhibitors to factor VIII in patients with hemophilia A. Haemophilia 2002; 8: 2739.
  • 45
    Ewenstein BM, Hoots WK, Lusher J, De Michele D, White GC, Adelman B, Naden K. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85 (Suppl. 10): 359.
  • 46
    Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia. Blood 2000; 95: 13249.
  • 47
    Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40–CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 27507.
  • 48
    Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J, Hemophilia A. Mutation types determine risk of inhibitor formation. Thromb Haemost 1995; 74: 14026.
  • 49
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe hemophilia A due to intron 22 inversion with and without inhibitors to factor VIII. Thromb Haemost 1997; 77: 23642.
  • 50
    Herzog RW, High KA. Problems and prospects in gene therapy for hemophilia. Curr Opin Hematol 1998; 5: 3216.
  • 51
    Kaufman R. Advances toward gene therapy for hemophilia at the millennium. Human Gene Ther 1999; 10: 2091107.
  • 52
    Thompson AR. Gene therapies for the hemophilias. Med Ther 2000; 2: 58.
  • 53
    Pfeifer A, Verma IM. Gene therapy: promises and problems. Ann Rev Genomics Huma Genet 2001; 2: 177211.
  • 54
    Kelley K, Verma I, Pierce GF. Gene therapy: realty or myth for the global bleeding disorder community? Haemophilia 2002; 8: 2617.
  • 55
    Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 25761.
  • 56
    Powell JS, Ragni MV, White GC, Lusher J, Hillman-Wiseman C, Cole V, Jolly D, Ramanathan-Girish S, Roehl H, Lu B, Hurst D. Results from one year follow up of a phase I trial of FVIII gene transfer for severe hemophilia a using a retroviral construct administered by peripheral intravenous infusion. Blood 2001; 98: 693a.
  • 57
    Roth DA, Tawa NE, O'Brien J, Treco DA, Seldon RF. Non viral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 173542.
  • 58
    Roth DA, Tawa NE, Proper JA, Morrel EM, Schnetz TJ, Treco DA, Seldon RF. Implantation of non-viral ex vivo genetically modified autologous dermal fibroblasts that express B-domain deleted human factor VIII in 12 hemophilia A study subjects. Blood 2002; 100: 116a.
  • 59
    Kay MA, High K, Glader B, Manno CS, Hutchinson S, Dake M, Razavi M, Kaye R, Arruda VR, Herzog R, McClelland A, Rustagi P, Johnson F, Rasko JEJ, Hoots K, Blatt P, Leonard GB, Addya K, Konkle B, Chew A, Couto L. A phase I/II clinical trial for liver directed AAV-mediated gene transfer for hemophilia B. Blood 2002; 100: 115a.